Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13742763 | 0.88 | CYP1A2 (0.64) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL3305050 | 0.86 | PIN1 (0.48) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL13742855 | 0.86 | HTT (0.49) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL13742811 | 0.84 | CYP2D6 (0.57) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL14396701 | 0.83 | POLB (0.47) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL31733017 | 0.83 | POLB (0.47) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL17595223 | 0.83 | SLC29A1 (0.53) | PIN1POLBMPOCYP1A2CYP3A4 | |
| SCHEMBL2120063 | 0.81 | CDC7 (0.61) | PIN1POLBCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL31186612 | 0.81 | CDC7 (0.61) | PIN1POLBCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL14850600 | 0.80 | ADORA2A (0.43) | PIN1POLBMPOCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016038562-A1 | THIOGUANINE DERIVATIVES | MALAYSIAN INSTITUTE OF PHARMACEUTICALS AND NUTRACEUTICALS (MY) | 2016-03-17 | — | — | WO | claimed |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| WO-1993014103-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| US-5017701-A | Process for the preparation of purine derivatives | BEECHAM GROUP, P.L.C. (GB) | 1991-05-21 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0352953-A2 | Process for the preparation of purine derivatives | BEECHAM GROUP PLC (GB) | 1990-01-31 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PIN1 2640/4885POLB 382/4885MPO 1082/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PIN1 2640/4885POLB 382/4885MPO 1082/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | PIN1 2640/4885POLB 382/4885MPO 1082/4885 |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 2059/4885POLB 27/4885MPO 1975/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PIN1 1459/4885POLB 623/4885MPO 3938/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | PIN1 3431/4885POLB 2157/4885MPO 4859/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 1953/4885POLB 28/4885MPO 2010/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | PIN1 2640/4885POLB 382/4885MPO 1082/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | PIN1 2695/4885POLB 3074/4885MPO 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.